Economy

Nabriva Therapeutics AG's (NBRV) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Nabriva Therapeutics AG's (NBRV)

Nabriva Therapeutics plc - Ordi shares had a trading volume of 209K by the end of trading on Friday. The stock has an average rating of Buy and an average target price of $16.25.

Investors are feeling more bearish of late as indicated by the motion in short interest. The stock had a rise in short interest of 3.44% between July 31, 2017 and August 15, 2017. Specifically, the ECR rates were 87.3% for lefamulin and 90.2% for moxifloxacin with/without linezolid.

Additionally, here are a few investment firms who have increased or decreased their stake in (NBRV). The total value of its holdings decreased 12.7%. Royal Bank of Canada now owns 52,807 shares of the biotechnology company's stock valued at $553,000 after buying an additional 8,650 shares during the last quarter. Morgan Stanley owns 3,584 shares valued at $43,000. The total value of its holdings increased 500.0%.

As of the end of the quarter Tower Research Capital LLC (trc) had acquired 409 shares growing its stake by 435.1%. Tower Research Capital LLC (trc) now controls 503 shares valued at $6,000. Acuta Capital Partners, LLC reduced its investment by selling 28,673 shares a decrease of 4.1% from 12/31/2016 to 03/31/2017. Acuta Capital Partners LLC now owns 706,383 shares of the company's stock valued at $4,210,000 after buying an additional 122,862 shares in the last quarter. The value of the position overall is up by 93.2%. Zacks Investment Research raised Nabriva Therapeutics AG from a hold rating to a buy rating and set a $11.00 price objective for the company in a report on Saturday, May 27th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company.

The company will host a conference call this morning at 8:30 am ET to discuss the results.

Shares last traded at $7.40 significantly below the 50 day moving average of $9.21 and much lower than the 200 day moving average of $10.28. The 50 day moving average was down $-1.81 or -19.65% whereas the 200 day average was down by -27.99%. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks' consensus estimate of ($5.83) by $5.29.

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. I am extremely proud and appreciative of the Nabriva Therapeutics team that has advanced lefamulin, which has the potential to be the first in a new class of antibiotics for CABP in more than 15 years, from initial discovery in our labs to this important milestone. This is the first of two phase 3 clinical trials needed to seek regulatory approval for lefamulin. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). It is also developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics AG in 2007.



Like this

Latest


18 September 2017
People Hurt After 2 Buses Collide In Flushing, Queens
The second bus features a logo on the back for Dahlia Travel and Tours, a Flushing-based company. A twisted wreck between two buses in Queens has left multiple people injured, police say.

18 September 2017
Apple Bans Misleading Apps From App Store, Introduces Face ID, ARKit Guidelines
Interestingly, apps can be used to offer 100 percent of funds from one person to another without using In-App Purchases. As such, the ban will put up against apps "including content or services that it does not actually offer".

18 September 2017
Jones Lang LaSalle Incorporated (NYSE:JLL) Price to Book & Valuation Review
This stock has garnered attention of analysts and investors over the past few weeks as the stock has come into mainstream focus. The Fort Washington Investment Advisors Inc holds 492,123 shares with $49.72 million value, up from 167,420 last quarter.

18 September 2017
Boy killed by falling soccer goal post in midtown, police say
The dead boy, who lived on Riverside Drive, was transported to Mount Sinai Saint Luke's Hospital, where he was pronounced dead. Tomasso Cerase was hanging off a goal post just before it splintered and fatally struck him in the head, cops said.

18 September 2017
Al Jazeera's Snapchat account banned in Saudi
At the behest of the Saudi Arabia government, Snap removed the Al Jazeera Discover Publisher Channel in that country. According to Snapchat, the company follows the laws, rules, and regulation of the country in which it operates.

18 September 2017
New variant of Xiaomi Redmi Note 5A launched, available in China
The device is powered by a 2.0GHz Qualcomm Snapdragon 625 octa-core processor paired with Adreno 506 GPU to handle the graphics. That means you can either use this as a dual-SIM phone without memory card option or single-SIM phone with memory card option.

18 September 2017
Cracker Barrel Old Country Stor (NASDAQ:CBRL) Sees Significantly Higher Trading Volume
Public Employees Retirement System of OH raised its stake in Cracker Barrel Old Country Store by 4.7% in the 1st quarter. BlackRock Inc. grew its holdings in shares of Cracker Barrel Old Country Store by 18,784.9% during the first quarter.

18 September 2017
Delhi Police arrest suspected al-Qaeda operative
Ahmed was arrested by Delhi Police's special cell and was later handed over to the West Bengal police. Meanwhile, Haq is now undergoing interrogation and more details regarding his arrest are awaited.

18 September 2017
Lenovo launches the Tab 4 series with a Standard and Plus variant
The OS is Android Nougat 7.0 and the device has a 5MP rear/primary camera complementing a 2MP front camera. The Tab 4 8 and Tab 4 8 Plus have been priced at Rs 12,990 and Rs 16,990, respectively.

18 September 2017
Moto X4 India launch imminent as Motorola puts up teasers on Twitter
The camera of Moto X4 is a dual camera setup with a 12MP sensor with dual autofocus Pixel sensor and an 8MP ultra wide angle lens. While the tweets make no mention of the Moto X4, it is all but confirmed that it is hinting at the imminent launch of the device.



Recommended